↑  Read the latest from the desks  ·  fresh intelligence, published daily✦Quiet reading✦No ads, ever

✦Corporate brand & media services✦Made in Virginia Beach since 1997✦

Invivyd: Old boat (three warning signs)Old boat

Invivyd $IVVD

Grew revenue 110% in FY2025 to $53 million, operating margin -104% against a -15.8% median for biological products, (no diagnostic substances), equity 87.2% of assets.

Last filing10-Q, 16 Nov 2026

Next year, 80%$83M–$148M
Growth, on the year110.5%
Operating margin−104.0%
Equity of assets87.2%
Your call, sealedNext year’s revenue, your range. Sealed now, graded when the annual report lands.
Edgarette’s full reading · exposure, experience, soundness, credibility, range

🫧 Edgar looked up INVIVYD, INC. ($IVVD). Last filing: 10-Q, 2026-11-16. 13 event filings (8-K) in the past twelve months.

🔖 Exposure: revenue $53.4M (FY2025). Experience: revenue up 110.5% on the year; operating margin -104.0%, up from -696.8%. Soundness: equity 87.2% of assets, return on equity -21.7%. Credibility: 3 audited years, moderate weight. Range: 80% of past cases like this landed between $82.5M and $148.2M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -104.0% against a -15.8% median; growth 110.5% against 21.4%.

Read from its own SEC filings · nothing written, nothing inferred

INVIVYD, INC. against its own record and its peers
Operating marginPeer median -15.8%-104.0%Revenue, on the yearPeer median 21.4%110.5%Equity of assetsPeer median 58.6%87.2%Return on equityPeer median -6.5%-21.7%Gold tick: the median of 25–31 peers with $50M+ revenue in biological products, (no diagnostic substances)

Speed and cash · fiscal 2025

Cash flow (op · inv · fin · free)−$58M · −$0M · $216M · −$58M
Investment book (cash · short · long)$227M · — · — · current ratio 7.24
Revenue swing · equity of assets— · 87.2%

The figures, as filed

Fiscal year end2025-12-31
Revenue$53M
Revenue, on the year110.5%
Revenue, a year over the record—
Operating margin−104.0%
Operating margin, prior year−696.8%
Net margin−98.2%
Research and development$38M · 71.7% of revenue
Total debt—
Equity of assets87.2%
Return on equity−21.7%
Payout of profit—
Dividend per share—
Earnings per share$-0.3
Book value per share$1.40
Revenue per share$0.31
Shares outstanding172,212,902
Audited years read3

Peers: the median of 31 filers with $50M+ revenue in biological products, (no diagnostic substances).

Classic signals · fiscal 2025Altman Z″ -0.36 distress zone 1968Piotroski F 3 of 9 middling 2000Beneish M not enough filed detail (needs receivables, cost of revenue, PP&E, depreciation, SG&A for two years)Sloan accruals 2.8% earnings backed by cash 1996DuPont ROE -34% = margin -98.2% × turns 0.26 × leverage 1.31

What a terminal subscription used to buy, a filing and arithmetic now give anyone. Published method, from the same filings. Display only: nothing here moves the range or its receipt. Why? →

Health HarborInvivyd sails as Old boat3 warning signs

Health watch · 12 monthsExchange listing notice or transferDirector or officer change

Versus peersoperating margin −104.0% vs a −15.8% median · revenue growth 110.5% vs 21.4% · cash beats 8% of its size class · growth beats 95% 31 biological products filers

Trend · last year to this▲operating margin −696.8% → −104.0% · ▲revenue $25.4M → $53.4M

See all 65 biological products companies on POPS4 sorted from the newest ship to the boat at the dock
#CompanyConditionOperating marginRevenue growthSales
1New shipExelixisEXELNew ship37.6%7.0%$2.3B
2New shipHalozyme TherapeuticsHALONew ship33.6%37.6%$1.4B
3New shipNeurocrine BiosciencesNBIXNew ship21.6%21.4%$2.9B
4New shipVaxartVXRTNew ship7.6%726.7%$237.3M
5Sound shipMaze TherapeuticsMAZESound ship34.4%—$167.5M
6Sound shipAmgenAMGNSound ship24.7%10.0%$36.8B
7Sound shipRepligenRGENSound ship7.5%16.4%$738.3M
8Sound shipExozymesEXOZSound ship−2563.5%—$0.1M
9Sound shipLexeo TherapeuticsLXEOSound ship−9252.1%—$0.7M
10Sound shipCalidi BiotherapeuticsCLDISound ship−51395.6%—$0.0M
11Weathered boatMonte Rosa TherapeuticsGLUEWeathered boat−43.8%63.5%$123.7M
12Weathered boatAlpha CognitionACOGWeathered boat−221.7%—$10.2M
13Weathered boatHumacyteHUMAWeathered boat−5306.0%—$2.0M
14Weathered boatCandel TherapeuticsCADLWeathered boat−27777.6%0.0%$0.1M
15Weathered boatRevolution MedicinesRVMDWeathered boat——$0.0M
16Weathered boatScholar Rock HoldingSRRKWeathered boat—−100.0%$0.0M
17Weathered boatAllogene TherapeuticsALLOWeathered boat—−100.0%$0.0M
18Weathered boatInhibikase TherapeuticsIKTWeathered boat—−100.0%$0.0M
19Weathered boatNKGen Biotech1845459Weathered boat—−100.0%$0.0M
20Old boatChampions OncologyCSBROld boat−1.9%4.4%$59.4M
21Old boatFennec PharmaceuticalsFENCOld boat−14.1%−6.1%$44.6M
22Old boatTarsus PharmaceuticalsTARSOld boat−15.7%146.7%$451.4M
23Old boatCentury Therapeutics, Inc.IPSCOld boat−15.8%1556.8%$109.2M
24Old boatCurisCRISOld boat−60.5%−13.4%$9.4M
25Old boatRegenxbioRGNXOld boat−94.6%104.5%$170.4M
26Old boatInvivydIVVD · this companyOld boat−104.0%110.5%$53.4M
27Old boatPelthos TherapeuticsPTHSOld boat−193.1%—$16.8M
28Old boatDyadic InternationalDYAIOld boat−232.8%−11.6%$3.1M
29Old boatX4 PharmaceuticalsXFOROld boat−247.4%1250.5%$35.1M
30Old boatLenz TherapeuticsLENZOld boat−477.5%—$19.1M
31Old boatAlectorALECOld boat−741.3%−79.1%$21.0M
32Old boatRecursion PharmaceuticalsRXRXOld boat−867.9%26.9%$74.7M
33Old boatAligos TherapeuticsALGSOld boat−4024.9%−39.5%$2.2M
34Old boatPrime MedicinePRMEOld boat−4498.1%55.3%$4.6M
35Old boatCardiff OncologyCRDFOld boat−8256.3%−13.2%$0.6M
36Old boatInhibrx BiosciencesINBXOld boat−10386.5%550.0%$1.3M
37Old boatCrispr Therapeutics AGCRSPOld boat−18933.6%−90.6%$3.5M
38Old boatEntera BioENTXOld boat−27450.0%−76.8%$0.0M
39Old boatBioatlaBCABOld boat−32146.7%—$0.3M
40Old boatAtyr PharmaATYROld boat−40856.3%−19.1%$0.2M
41Old boatInmune BioINMBOld boat−94766.0%257.1%$0.1M
42Old boatCreative Medical Technology HoldingsCELZOld boat−102380.2%−45.5%$0.0M
43Old boatSenti Biosciences HoldingsSNTIOld boat−312631.8%—$0.0M
44Old boatEloxx PharmaceuticalsELOXOld boat—−100.0%$0.0M
45Old boatPharmacyte BiotechPMCBOld boat——$0.0M
46Old boatArtiva BiotherapeuticsARTVOld boat—−100.0%$0.0M
47Rotting at the dockZeo ScientifiXZEOXRotting at the dock−103.6%12.5%$5.2M
48Rotting at the dockMeiraGTx HoldingsMGTXRotting at the dock−130.2%144.6%$81.4M
49Rotting at the dockModernaMRNARotting at the dock−158.1%−39.9%$1.9B
50Rotting at the dockLineage Cell TherapeuticsLCTXRotting at the dock−251.6%53.2%$14.6M
51Rotting at the dockSangamo TherapeuticsSGMOQRotting at the dock−306.5%−31.6%$39.6M
52Rotting at the dockVoyager TherapeuticsVYGRRotting at the dock−326.6%−49.5%$40.4M
53Rotting at the dockCoherus Oncology, Inc.CHRSRotting at the dock−429.5%59.8%$42.2M
54Rotting at the dockVir BiotechnologyVIRRotting at the dock−699.2%−7.6%$68.6M
55Rotting at the dockScilex Holding CompanySCLXRotting at the dock−1143.7%−46.5%$30.3M
56Rotting at the dockSurrozen, Inc./DESRZNRotting at the dock−1210.6%−67.4%$3.5M
57Rotting at the dockTscan TherapeuticsTCRXRotting at the dock−1315.4%266.7%$10.3M
58Rotting at the dockCaribou BiosciencesCRBURotting at the dock−1329.4%11.7%$11.2M
59Rotting at the dockOcugenOCGNRotting at the dock−1425.7%8.8%$4.4M
60Rotting at the dockFate TherapeuticsFATERotting at the dock−2222.4%−51.2%$6.6M
61Rotting at the dockPluriPLURRotting at the dock−2454.5%−24.0%$1.0M
62Rotting at the dockAbpro HoldingsABPORotting at the dock−5421.3%50.0%$0.2M
63Rotting at the dockVivoSim LabsVIVSRotting at the dock−8768.7%−9.0%$0.1M
64Rotting at the dockAim ImmunotechAIMRotting at the dock−13254.5%−48.2%$0.1M
65Rotting at the dockProKidneyPROKRotting at the dock−18477.8%1075.0%$0.9M

From each company’s own POPS4 card. Green beats the industry median above, red trails it. Not a rating and not investment advice.

Sailing speed follows growth: 110.5% a year crosses the harbor in 30 seconds.

🌊 Visit the Bay →
The warning signs
  • Operating cash flow was negative
  • Operating loss a margin of -104.0% in FY2025
  • Revenue is hard to predict its 80% range is ±28%

Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an operating loss; negative free cash flow outside regulated utilities; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.

Recent filings
Measured, not prophesiedSuccess tools: score it, compare it, see its fieldFour questions. Scored against the SEC filings of the companies in your field.

Try InstagramSpriteHokaDisneyGatoradee.l.f.

Each benchmark is the median of SEC filers in your industry code, from their own audited filings, read on the filing boards. Reporting, not investment advice.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · Open in Excel (CSV) · Ten-year table (CSV) ·

1 · Follow

Follow their filings

Or tap watch on any row above. You get the company’s live filing feed and Edgar’s card. Nothing to sign up for.

On Bluesky: follow Edgar & Edgarette.

2 · Price it

A new leader’s rebrand and launch

Priced live by the same engine as our estimator, from the catalogue at wholesale.

Price the printing · Open the full estimator

✦ Build the kit yourself
3 · Confirm

Check it with Jenny

Most buyers check what they found, or what their AI found, with one person before they commit. That person is the principal.

Jenny Huang Goodman MPA MSc MHSA, Principal

Book a time info@pops4.com
Independence. Every range, flag and score on these boards is identical for everyone. Clients of POPS4 or Hako Shikin receive no different numbers, no earlier access and no say in what is published. The service lines shown beside each board describe work we do; they never change the data. For reviewers: Method · Terms of use · Status
Free · unsponsored · source-linked

Clean data. No ads. Not now, not later.

Nine boards reading every SEC filing the business day after it lands, from the settled SEC daily index, ten editorial desks publishing daily, an open endpoint other AIs can query, and a 70,000-product house behind all of it. This is the public record end of it.

Every row is a filing.Straight from the company's own SEC document, linked. Nothing written, nothing inferred.
Nobody is watching you read.No ad trackers, no cookies from us. Our page counts are cookieless.
One email, one job.Watch a company and we hold that address for the alert alone. One tap ends it. Never shared, never passed on.
The house pays for this.Corporate event programs, corporate supplies and branded merchandise, since 1997. That is what funds the desks, under the house's own vendor standards.
Free to reuse with credit · CC BY 4.0 · how the boards are built
Data & Disclosure Notice: Edgar and Edgarette are automated software. Every figure on this page is calculated by software from public filings made by companies and funds with the U.S. Securities and Exchange Commission (EDGAR) and is published without individual human review. The accuracy and completeness of those filings are the responsibility of the filers; reports can contain errors and can be amended. Figures are shown as filed and as of each filing's date, and this page may be corrected or updated without notice. Ranges, expected returns, rankings, boats and other measures are statistical descriptions of past filings, not ratings, price forecasts, company guidance or recommendations; past results do not guarantee future results. This is general information published for all readers, not advice tailored to any person's portfolio, needs or circumstances, and nothing here is financial, investment, actuarial, legal, tax or other professional advice. Actuaries and other professionals who use these figures remain responsible for reviewing them for reasonableness and consistency against the original filings and for disclosing their reliance on them. No company, fund or reinsurer pays to be included or ranked. Provided as is, without warranty of any kind. Not affiliated with or endorsed by the SEC or by any company, fund or reinsurer named. All trademarks remain the property of their owners.